LU:NYSELufax Holding Ltd Analysis
Data as of 2026-06-12 - not real-time
$1.33
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Technical outlook: Lufax (LU) is trading at $1.33, well below its 20‑day ($1.59), 50‑day ($1.79) and 200‑day ($2.56) simple moving averages, with a bearish MACD (-0.14) and an RSI of 18.8 indicating oversold conditions. The price sits just above the identified support level of $1.29 and faces resistance near $1.92, while 30‑day volatility is high at ~40% and beta exceeds 1.5, suggesting amplified market swings.
Fundamental & risk backdrop: The company reports a 19.5% YoY revenue decline, negative profit margin (-6.99%), and a staggering debt‑to‑equity ratio of 86, underscoring financial strain despite a low forward PE (~4.9) and ultra‑cheap price‑to‑book (0.10). Compounding the weakness, a securities class‑action lawsuit stemming from the removal of its auditor and alleged undisclosed related‑party transactions has triggered a ~14% price drop, elevating regulatory and legal risk.
Fundamental & risk backdrop: The company reports a 19.5% YoY revenue decline, negative profit margin (-6.99%), and a staggering debt‑to‑equity ratio of 86, underscoring financial strain despite a low forward PE (~4.9) and ultra‑cheap price‑to‑book (0.10). Compounding the weakness, a securities class‑action lawsuit stemming from the removal of its auditor and alleged undisclosed related‑party transactions has triggered a ~14% price drop, elevating regulatory and legal risk.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 8/10
Key Factors
- Bearish technical indicators and proximity to support
- Ongoing securities class‑action lawsuit
- High leverage and negative earnings
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Potential resolution of legal matters
- Extremely low valuation multiples offering upside if fundamentals improve
- Continued volatility and debt burden
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Value‑oriented pricing may attract contrarian investors
- Uncertainty around Chinese regulatory environment
- Need for sustainable earnings turnaround and balance‑sheet deleveraging
Key Metrics & Analysis
Financial Health
Revenue Growth-19.50%
Profit Margin-6.99%
P/E Ratio4.9
ROE-2.07%
ROA3.06%
Debt/Equity86.34
P/B Ratio0.1
Op. Cash Flow$12.5B
Free Cash Flow$9.5B
Industry P/E16.8
Technical Analysis
TrendBearish
RSI18.8
Support$1.29
Resistance$1.92
MA 20$1.59
MA 50$1.79
MA 200$2.56
MACDBearish
VolumeStable
Fear & Greed Index89.86
Valuation
Fair Value$91.16
Target Price$2.78
Upside/Downside109.23%
GradeUndervalued
TypeValue
Risk Assessment
Beta1.52
Volatility39.98%
Sector RiskHigh
Reg. RiskHigh
Geo RiskHigh
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.